Article

Psoriasis Flares Associated with Short-Term Air Pollution Exposure

Author(s):

Previous research indicated that the worsening of different inflammatory cutaneous diseases had been associated with exposure to air pollution.

Francesco Bellinato, MD

Francesco Bellinato, MD

A new cross-sectional study from Italy suggested that air pollution could be a trigger factor for psoriasis flares.

Previous research indicated that the worsening of different inflammatory cutaneous diseases such as atopic dermatitis, photoaging, and acne had been associated with exposure to air pollution. Psoriasis specifically has been defined by a relapsing-remitting course and selected environmental factors such as infection or drugs may trigger disease flares.

Francesco Bellinato, MD, Department of Medicine at the University of Verona, and a team of investigators set out to find whether short-term exposure to environmental air pollution was associated with psoriasis flares.

The Methods

Bellinato and colleagues analyzed data from the electronic medical records of the Dermatology Unit of the University Hospital of Verona on patients with chronic plaque psoriasis. The analysis occurred from September 2013 to January 2020.

Inclusion criteria for the study were patients with any continuous systemic treatment for at least 6 months before a dermatological visit, patients with at least 2 consecutive measurements of Psoriasis Area and Severity Index (PASI) at 3 ro 4 month intervals, patients with residency within 10 km of the air pollutant collection point, and patients with at least 1 disease flare, defined PASI increase of 5 or greater between 2 clinical visits between 3 months.

Sex, disease duration, and systemic treatment with conventional and biologic therapies were also considered.

From there, air pollutant daily concentrations of the Verona area related to the same period were collected from the official bulletin of the Italian Institute for Environmental Protection and Research (ISPRA), with the following air pollutants being available: CO, NO2, NOx, C6H6, PM10, and PM2.5.

Short-term exposure was defined as mean and area under the curve (AUC) concentration in the 60 days immediately before the dermatological visit and the PASI assessment.

Patients were included in the cross-sectional analysis if they received any systemic treatment for 6 or more months, with grader 2 or higher PASI assessment.

The Findings

Bellinato and colleagues recruited a total of 957 patients with plaque psoriasis, and a total of 4398 follow-up visits were included in the study.

Additionally, more than 15,000 air pollutant concentration measurements were taken from the ISPRA.

Among the overall cohort, 369 (38.6%) patients with psoriasis flare were included in the case-crossover study. The team observed that concentrations of all pollutants were significantly higher in the 60 days before psoriasis flare (median PASI at the flare 12; IQR, 9-18) compared to the control visit (median PASI 1; IQR, 1-3, P < .001).

Exposure to mean PM10 over 20 μg/m3 and mean PM2.5 over 15 μg/m3 in the 60 days before assessment were associated with a higher risk of PASI 5 or greater point worsening (adjusted odds ratio [aOR], 1.55; 95% CI, 1.21-1.99; and aOR, 1.25; 95% CI, 1.0-1.57, respectively) in the cross-sectional analysis, and sensitivity analyses that stratified for trimester of evaluation featured similar results.

Investigators concluded that short-term air pollution exposure was associated with increased psoriasis activity and likelihood of psoriasis flares. However, additional data was recommended.

“Further study is needed to examine whether these findings generalize to other populations and to better understand the mechanisms by which air pollution may affect psoriasis disease activity,” the team said.

The study, "Association Between Short-term Exposure to Environmental Air Pollution and Psoriasis Flare," was published online in JAMA Dermatology.

Related Videos
A panel of 3 experts on atopic dermatitis
A panel of 3 experts on atopic dermatitis
A panel of 3 experts on atopic dermatitis
Discussing Interim Findings on Nemolizumab for Atopic Dermatitis, with Diamant Thaçi, MD
Responding to FDA Approval of Lebrikizumab for Atopic Dermatitis, with Andrew Alexis, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.